
浏览全部资源
扫码关注微信
纸质出版日期:2016
移动端阅览
秦劭晨, 梁伟雄, 温晓文, 等. 注射用羟基红花黄色素A治疗急性缺血性中风血瘀证疗效观察[J]. 中国实验方剂学杂志, 2016,22(21):157-161.
QIN Shao-chen, LIANG Wei-xiong, WEN Xiao-wen, et al. Clinical Efficacy of Hydroxysafflor Yellow A Injection for Acute Ischemic Stroke with Blood Stasis Syndrome Treated[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(21): 157-161.
秦劭晨, 梁伟雄, 温晓文, 等. 注射用羟基红花黄色素A治疗急性缺血性中风血瘀证疗效观察[J]. 中国实验方剂学杂志, 2016,22(21):157-161. DOI: 10.13422/j.cnki.syfjx.2016210157.
QIN Shao-chen, LIANG Wei-xiong, WEN Xiao-wen, et al. Clinical Efficacy of Hydroxysafflor Yellow A Injection for Acute Ischemic Stroke with Blood Stasis Syndrome Treated[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(21): 157-161. DOI: 10.13422/j.cnki.syfjx.2016210157.
目的:评价注射用羟基红花黄色素A治疗急性缺血性中风血瘀证的中医证候疗效,及对氧化应激指标超氧化物歧化酶(SOD)和丙二醛(MDA)的影响。方法:纳入符合条件的急性缺血性中风血瘀证患者共71例,随机分为治疗组与对照组,治疗组35例,予羟基红花黄色素A注射液50 mg/次,对照组36例,予灯盏细辛注射液30 mg/次,治疗药物加入0.9%生理盐水250 mL中静脉滴注,1次/d,治疗14 d。以3个不同时点(用药前,用药后30 d,用药后90 d)的血瘀证评分作为临床结局指标,对两组治疗急性缺血性中风血瘀证的中医证候疗效进行评价;检测治疗前及治疗后30 d患者血清SOD和MDA水平。结果:中医证候疗效比较,治疗组中医血瘀证的疗效优于对照组(P<0.05)。中医证候的协方差分析,治疗30 d后,治疗组得分下降(0.69±2.48)分,高于对照组的(0.28±1.16)分,校正基线后,治疗组30 d疗效优于对照组(P<0.05);治疗90 d后,治疗组下降(1.17±2.68)分,高于对照组(0.42±1.40)分,校正基线后,治疗组90 d疗效优于对照组(P<0.01)。血清SOD和MDA比较,治疗后治疗组SOD水平高于对照组(P<0.01),MDA水平低于对照组(P<0.01)。结论:注射用羟基红花黄色素A与灯盏细辛注射液均能不同程度改善血瘀证患者的临床症状,对于血瘀证均显示出一定疗效,羟基红花黄色素A对血瘀证的疗效优于灯盏细辛,其作用机制可能与减轻氧化应激损伤有关。
Objective: To evaluate the clinical efficacy of hydroxysafflor yellow A (HSYA) injection for traditional Chinese medicine (TCM) syndrome of acute ischemic stroke with blood stasis syndrome
and investigate its effects on levels of superoxide dismutase (SOD) and malondialdehyde (MDA). Method: A total of 71 eligible cases with acute ischemic stroke with blood stasis were randomly divided into treatment group(35 cases) and control group (36 cases). Patients in treatment group received HSYA injection
50 mg/time
and patients in control group received Erigeron breviscapus injection
30 mg/time. Both of the two kinds of medicines were dissolved into 250 mL 0.9%normal saline for intravenous drip
once per day for 14 days. Scores of blood stasis syndrome from three different time points (before drug medication
30 days after drug medication and 90 days after drug medication) were regarded as the clinical outcome indexes to evaluate their efficacy for TCM syndrome between control group and treatment group in treatment of acute ischemic stroke (blood stasis syndrome). Levels of SOD and MDA were tested before and 30 days after treatment. Result: In comparison of efficacy for TCM syndrome
the treatment group was better than control group (P<0.05). The Covariance analysis of TCM syndrome showed that 30 days after treatment
the scores decrease in treatment group (0.69±2.48) points was higher than that in control group (0.28±1.16) points
and after correcting baseline
the efficacy in treatment group was better than that in control group (P<0.05)
while 90 days after treatment
the scores decrease in treatment group (1.17±2.68) points was higher than that in control group (0.42±1.40) points
and after correcting baseline
the efficacy in treatment group was better than that in control group (P<0.01). Levels of SOD in treatment group were higher than those in control group after treatment(P<0.01)
but the levels of MDA in treatment group were lower than those in control group (P<0.01). Conclusion: Both HSYA injection and Erigeron breviscapus injection could improve the clinical symptoms to different degrees in patients with blood stasis syndrome. Both of them showed certain efficacy for blood stasis syndrome
but the efficacy in treatment group was superior to that in control group. Its mechanism may be related to relieving oxidative stress injury.
0
浏览量
4
下载量
4
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621